This is an aggregated industry headline. Read the full story at PharmaVoice →
Galimedix is keeping the amyloid hypothesis alive
The right target but the wrong approach? Why Galimedix's CEO believes the company has found an edge in treating Alzheimer's disease with an amyloid drug.
By PharmaVoice
· Jul 14, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become…
The WeekFierceBiotech ↗
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to San…
The WeekSTAT News ↗
Blumenthal, Hawley press UnitedHealth, Humana, CVS for documents related to using AI to deny or delay care.…